Markets· August 16, 2026 at 10:01 p.m.
Avita Medical Boosts 2026 Revenue Outlook on Q2 Sales Growth
Key takeaways
- Avita Medical raised its 2026 revenue outlook
- Q2 sales climbed by 18% year-over-year
- The company aims for cash-flow breakeven in Q4
Avita Medical, a regenerative medicine company, has raised its 2026 revenue outlook to $86 million–$89 million from $80 million–$85 million following a 18% year-over-year increase in Q2 sales to $21.7 million. The company aims for cash-flow breakeven in the fourth quarter. The improved financial performance, with a narrowed net loss and reduced quarterly cash use, is attributed to growth across Avita's product portfolio and in U.S. and international markets.
